NAPHTHYLACETIC ACIDS

FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to organic chemistry, namely to a compound of formula I and to their pharmaceutically acceptable salt or their ester, wherein W means C(H), C(H)-C(H)or C(H)(CH); X is specified in a group consisting of: (1) O, (2) N(H), (4) S, (5)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LI CHEHN, FARIBORZ FIRUZNIA, EHRIK MERTTS, CHZHEHN'SHAN' CHZHAN, SUNSAU SO, POL DZHILLESPAJ, JUN' KHEH, TAJAN' LIN', KHONIN JUN
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to organic chemistry, namely to a compound of formula I and to their pharmaceutically acceptable salt or their ester, wherein W means C(H), C(H)-C(H)or C(H)(CH); X is specified in a group consisting of: (1) O, (2) N(H), (4) S, (5) S(O) and (6) S(O); Y means carbon or nitrogen; Ris specified in a group consisting of: (1) hydrogen, (2) halogen, (3) methyl optionally substituted by fluorine, (4) Calkoxygroup optionally substituted by fluorine, (5) cyano group and (6) Calkylsulphonyl; Rmeans hydrogen, fluorine, chlorine or Calkoxygroup; Rmeans hydrogen, fluorine, chlorine, bromine or methyl; Ris specified in a group consisting of: (1) hydrogen, (2) halogen, (3) Calkyl optionally substituted by fluorine, (4) Ccycloalkyl, and (5) ethenyl; Rand Rare independently from each other specified in a group consisting of: (1) hydrogen, (2) halogen, (3) Calkyl, (4) cyanogroup and (5) Ccycloalkyl; Rmeans cyano group or S(O)-R, wherein Ris specified in a group consisting of: (1) Calkyl, (2) Ccycloalkyl, (4) Calkylamino group, (5) Cdialkylamino group, (6) lower heterocycloalkyl optionally substituted by halogen, Calkyl, or Calkoxycarbonyl and (7) 2-oxa-6-azaspiro[3.3]hept-6-yl, wherein lower heterocycloalkyl means a saturated or partially unsaturated non-aromatic ring fragment containing 3 to 7 atoms bound together to form a ring structure, wherein one, two or three ring atoms are heteroatoms, whereas the rest ring atoms are carbon atoms; and pharmaceutically acceptable esters represent methyl and ethyl acid esters of formula I acceptable as prodrugs. The invention also refers to a pharmaceutical composition based on the compound of formula.EFFECT: prepared are new compounds possessing the CRTH2 receptor antagonist or partial agonist activity.23 cl, 90 ex Группа изобретений относится к области органической химии, а именно к соединению формулы I и к их фармацевтически приемлемой соли или сложному эфиру, в которой W обозначает C(H), C(H)-C(H)или C(H)(CH); X выбран из группы, включающей: (1) O, (2) N(H), (4) S, (5) S(O) и (6) S(O); Y обозначает углерод или азот; Rвыбран из группы, включающей: (1) водород, (2) галоген, (3) метил, необязательно замещенный фтором, (4) Cалкоксигруппу, необязательно замещенную фтором, (5) цианогруппу и (6) Cалкилсульфонил; Rобозначает водород, фтор, хлор или Cалкоксигруппу; Rобозначает водород, фтор, хлор, бром или метил; Rвыбран из группы, включающей: (1) водород, (2) галоген, (3)